Research programme: cancer therapeutics and diagnostics - OncoTAb

Drug Profile

Research programme: cancer therapeutics and diagnostics - OncoTAb

Alternative Names: Monoclonal antibody - OncoTAb; TAB 004

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoTAb
  • Class Antibodies; Antibody diagnostics; Diagnostic agents; Radiopharmaceuticals
  • Mechanism of Action Diagnostic imaging enhancers; Mucin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Pancreatic cancer

Highest Development Phases

  • Preclinical Breast cancer; Pancreatic cancer

Most Recent Events

  • 19 Oct 2016 Research programme: cancer therapeutics and diagnostics - OncoTAb is available for licensing as of 19 Oct 2016. https://www.oncotab.com/science-technology/
  • 19 Oct 2016 OncoTAB has patents pending for cancer therapeutics and diagnostics worldwide (OncoTAB website,
  • 05 Oct 2016 OncoTAb receives SBIR grant from the National Cancer Institute for radionuclide monoclonal antibody development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top